Movement Alert｜KEYMED BIO-B Intraday Rise 5.98% in Regular Trading, Innovation Drug Shares Lifted by Strong Overseas Licensing Data

Market Focus10-20

On October 20, KEYMED BIO-B rose 5.98% in Regular Trading, trading at HK$86.45, with turnover of HK$173 million.

The move coincided with broad strength in Hong Kong innovative drug and CRO-related names after authorities said China’s innovative drug outbound technology licensing reached about $130 billion in the first three quarters, close to the full-year level last year.

Sector trading on the day showed a clear policy and industry-driven backdrop: innovative drug names including Lepu Biopharma, Hansoh Pharma, WuXi Biologics, GenFleet-B, Ascentage Pharma and KEYMED BIO-B were all higher, while separate market coverage also noted gains in healthcare outsourcing names such as Frontage and JOINN. For KEYMED BIO-B specifically, recent company fundamentals had already improved, with first-half revenue of RMB617 million, adjusted net profit of RMB1.218 billion, and core product sales of RMB393 million rising 132% year over year, providing supportive context for the stock’s reaction.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment